SQZ Biotechnologies Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

SQZ Biotechnologies şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-44.9%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-44.9%
Gelecekteki Temettü Verimi	0%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

SQZ Biotechnologies Company (NYSE:SQZ) Might Not Be As Mispriced As It Looks After Plunging 30%

Jun 26

We Think SQZ Biotechnologies (NYSE:SQZ) Needs To Drive Business Growth Carefully

Jan 05

SQZ Biotechnologies GAAP EPS of -$0.77 beats by $0.06, revenue of $3.5M misses by $0.76M

Nov 09

SQZ Biotech spikes as H.C. Wainwright initiates with Buy citing platform technology

Oct 20

Is SQZ Biotechnologies (NYSE:SQZ) In A Good Position To Deliver On Growth Plans?

Aug 20

SQZ Biotechnologies GAAP EPS of -$0.78 misses by $0.01, revenue of $3.22M misses by $0.97M

Aug 04

SQZ Biotechnologies names business chief as CFO

Jul 11

Time To Worry? Analysts Just Downgraded Their SQZ Biotechnologies Company (NYSE:SQZ) Outlook

May 17

Need To Know: Analysts Are Much More Bullish On SQZ Biotechnologies Company (NYSE:SQZ)

May 16

Newsflash: SQZ Biotechnologies Company (NYSE:SQZ) Analysts Have Been Trimming Their Revenue Forecasts

Mar 25

SQZ Biotechnologies Company (NYSE:SQZ) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Mar 20

We Think SQZ Biotechnologies (NYSE:SQZ) Can Afford To Drive Business Growth

Feb 01

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: SQZB şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: SQZB şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

SQZ Biotechnologies Piyasaya Karşı Temettü Getirisi

SQZB temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (SQZB)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.4%
Sektör Ortalaması (Biotechs)	2.4%
Analist tahmini (SQZB) (3 yıla kadar)	0%

Önemli Temettü: SQZB şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, SQZB şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: SQZB şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: SQZB herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Güçlü temettü ödeyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/24 05:57
Gün Sonu Hisse Fiyatı	2024/12/24 00:00
Kazançlar	2023/09/30
Yıllık Kazançlar	2022/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

SQZ Biotechnologies Company 7 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Tazeen Ahmad	BofA Global Research
Leah Rush Cann	Brookline Capital Markets
Thomas Shrader	BTIG

SQZ Biotechnologies Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

SQZ Biotechnologies Files Form 15

SQZ Biotechnologies Company Contemplates Bankruptcy.

SQZ Biotechnologies Company Contemplates Bankruptcy.

SQZ Biotechnologies Reports Data for Clinical Programs at the Society for Immunotherapy of Cancer Annual Meeting

SQZ Biotechnologies Company(OTCPK:SQZB) dropped from S&P TMI Index

New major risk - Market cap size

SQZ Biotechnologies Company (NYSE:SQZ) Might Not Be As Mispriced As It Looks After Plunging 30%

SQZ Biotechnologies Receives Written Notice from the NYSE Regarding Non-Compliance with Section 802.01B of the NYSE Listed Company Manual

First quarter 2023 earnings released: US$0.60 loss per share (vs US$0.75 loss in 1Q 2022)

Price target increased by 44% to US$19.00

Full year 2022 earnings: EPS and revenues exceed analyst expectations

SQZ Biotechnologies Receives Notice Regarding Continued Listing Standards From the New York Stock Exchange

We Think SQZ Biotechnologies (NYSE:SQZ) Needs To Drive Business Growth Carefully

SQZ Biotechnologies Receives FDA Fast Track Designation for its eAPC Therapeutic Candidate for Treatment of HPV16+ Tumors and Presents Clinical Data for Multiple Programs at the European Society for Medical Oncology Immuno-Oncology Congress

High number of new directors

Price target decreased to US$15.40

SQZ Biotechnologies Announces Resignation of Micah Zajic as Chief Financial Officer, Effective December 31, 2022

Price target decreased to US$17.67

Third quarter 2022 earnings released: US$0.77 loss per share (vs US$0.80 loss in 3Q 2021)

SQZ Biotechnologies Presents Cell Squeeze® Manufacturing Platform, Linked Antigen mRNA Preclinical Research, and COMMANDER-001 Phase 1/2 Clinical Trial in Progress Poster at Society for Immunotherapy of Cancer Annual Meeting

SQZ Biotechnologies GAAP EPS of -$0.77 beats by $0.06, revenue of $3.5M misses by $0.76M

SQZ Biotech spikes as H.C. Wainwright initiates with Buy citing platform technology

Sqz Biotechnologies Publishes Preclinical Research Demonstrating Sqz® Aac Platform’S Potential as an Effective Red Blood Cell-Derived Immunotherapy

SQZ Biotechnologies Company Presents Preclinical SQZ TIL Data Supporting Potential Ability of mRNA-Driven IL-2 and IL-12 Expression to Eliminate Need for Toxic Preconditioning and Systemic IL-2 Administration for Certain T Cell Therapies

SQZ Biotechnologies Company Announces Leadership Transition

Is SQZ Biotechnologies (NYSE:SQZ) In A Good Position To Deliver On Growth Plans?

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

SQZ Biotechnologies GAAP EPS of -$0.78 misses by $0.01, revenue of $3.22M misses by $0.97M

SQZ Biotechnologies and Collaborators Publish Technology Review on SQZ(R) APCs and Effective CD8 T Cell Activation

SQZ Biotechnologies Company Appoints Micah Zajic as Principal Financial Officer

SQZ Biotechnologies names business chief as CFO

SQZ Biotechnologies Company(NYSE:SQZ) dropped from Russell 2500 Index

Price target decreased to US$25.17

SQZ Biotechnologies Announces Generation of Dopaminergic Neurons from Human Pluripotent Stem Cells Through Single-Step Delivery of Six Cell-Fate Encoding RNAs

SQZ Biotechnologies Appoints Marshelle Smith Warren as Chief Medical Officer

Independent Director recently bought US$50k worth of stock

Price target decreased to US$27.50

SQZ Biotechnologies Announces Integrated Point-Of-Care Cell Therapy Manufacturing System Demonstrated Comparable or Better Performance Than A More Conventional Clean Room-Based Process

Consensus revenue estimates fall by 14%

Time To Worry? Analysts Just Downgraded Their SQZ Biotechnologies Company (NYSE:SQZ) Outlook

First quarter 2022 earnings: EPS and revenues miss analyst expectations

SQZ Biotechnologies Company Announces First Data Presentation on Non-Clinical Studies of Point-Of-Care Manufacturing System

Here's Why We're Watching SQZ Biotechnologies' (NYSE:SQZ) Cash Burn Situation

SQZ Biotechnologies Receives FDA Fast Track Designation for its Lead Cell Therapy Candidate for the Treatment of HPV16+ Tumors

Price target decreased to US$30.60

SQZ Biotechnologies Presents New eAPC Preclinical Data Demonstrating That Multiplexed mRNA Engineering of Immune Cells Increases Killer T Cell Activity In Vivo

SQZ Biotechnologies Publishes Comprehensive Preclinical Research on SQZ TAC Platform’s Ability to Induce Multiple Key Mechanisms of Antigen-Specific Tolerance and Protect Against Type 1 Diabetes

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$31.00

SQZ Biotechnologies Announces Publication of Comprehensive Preclinical Research on SQZ

SQZ Biotechnologies Company Announces FDA Clearance of Investigational New Drug (IND) Application for SQZ-eAPC-HPV

Here's Why We're Watching SQZ Biotechnologies' (NYSE:SQZ) Cash Burn Situation

SQZ Biotechnologies Company Announces Lead Cell Therapy Candidate Induced Radiographic, Symptomatic and Immune Response as Monotherapy in Post-Checkpoint Hpv+ Solid Tumor Patient

SQZ Biotechnologies Lead Cell Therapy Candidate Generated Monotherapy Clinical Response Correlated with Substantial CD8 T Cell Tumor Infiltration in HPV+ Solid Tumor at Highest Dose

SQZ Biotechnologies Company Announces Acceptance by Roche Accelerator in China

Third quarter 2021 earnings released: US$0.80 loss per share (vs US$7.03 loss in 3Q 2020)

SQZ Biotechnologies Announces First Autoimmune Disease Indication for Tolerizing Antigen Carrier (TAC) Platform

Second quarter 2021 earnings released: US$0.68 loss per share (vs US$6.05 loss in 2Q 2020)

Will SQZ Biotechnologies (NYSE:SQZ) Spend Its Cash Wisely?

SQZ Biotechnologies Company(NYSE:SQZ) dropped from Russell 2500 Growth Index

SQZ Biotechnologies Company Presents Regenerative Medicine Data Demonstrating Neuron Generation from Human Pluripotent Stem Cells with Single Delivery of mRNA Transcription Factor

SQZ Biotechnologies Company Tolerizing Antigen Carrier Program Induces Antigen-Specific Immune Tolerance in Preclinical Models Demonstrating Potential for Broad Applicability Across Autoimmune Diseases

SQZ Biotechnologies Presents Initial First-In-Human Data Demonstrates Investigational Cell Therapy is Safe and Can Stimulate Immune Responses in Certain Patients with Advanced or Metastatic HPV16+ Tumors

SQZ Biotechnologies Company to Present First Clinical Data at the American Society of Clinical Oncology Annual Meeting from Ongoing Phase 1 Study in Patients with Advanced or Metastatic HPV+ Tumors

Need To Know: Analysts Are Much More Bullish On SQZ Biotechnologies Company (NYSE:SQZ)

First quarter 2021 earnings released: US$0.59 loss per share (vs US$6.41 loss in 1Q 2020)

SQZ Biotechnologies to Present New Data on Rapid Cell Therapy Manufacturing Capabilities and Advantages in Cell Performance at ASGCT 2021

Newsflash: SQZ Biotechnologies Company (NYSE:SQZ) Analysts Have Been Trimming Their Revenue Forecasts

SQZ Biotechnologies Company (NYSE:SQZ) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Full year 2020 earnings released: US$9.35 loss per share (vs US$18.89 loss in FY 2019)

SQZ Biotechnologies to Present Preclinical Data on KRAS Tumor Targets and Next Generation SQZ eAPCs

New 90-day low: US$22.01

SQZ Biotechnologies Announces FDA Clearance of IND Application to Allow for Clinical Trial with SQZ Activating Antigen Carriers (SQZ AACs) in Patients with HPV+ Tumors

We Think SQZ Biotechnologies (NYSE:SQZ) Can Afford To Drive Business Growth

SQZ Biotech Presents Preclinical Data for SQZ APC and AAC Cellular Vaccine Platforms at SITC 2020, Including First-Time SQZ APC Combination Preclinical Data